Decoy Therapeutics Inc. (DCOY): Nasdaq/NYSE listing notice — Salarius receives Nasdaq delisting notice for bid price non-compliance; appeal planned

Decoy Therapeutics Inc.

Nasdaq notified Salarius on Dec 31, 2025 that bid price closed below $1.00 for 30 consecutive days.
Company ineligible for 180-day cure period due to reverse stock split within prior year.
Unless appeal filed by Jan 7, 2026, trading suspended Jan 9, 2026 and Form 25-NSE filed.
Salarius intends to appeal to Nasdaq Hearings Panel to stay suspension and present compliance plan.
No assurance that securities will remain listed on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Decoy Therapeutics Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)(iv)

Exact text from the filing

December 31, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq listing rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share (the “Minimum Bid Price Requirement”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasd

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-26-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.